secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-158951
Event type: leadership
Sentiment:  neutral
Materiality: 0.90
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval
--------------------------------------------------------------------------------

- Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.
- Conditional appointments of Stephen Hahn, Saira Ramasastry, Karen Vousden as new directors effective at same time.
- If proposals approved, Anand Parikh (current COO) will become CEO; Brian Stephenson will become CFO. Gerry remains General Counsel, Craver remains SVP Finance.
- Board adopted Severance and Change in Control Plan covering Parikh, Gerry, Craver with cash severance up to 18 months base salary and COBRA.
- Conversion Proposal involves issuance of >20% of common upon Series B preferred conversion, resulting in change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526158951/0001193125-26-158951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526158951/d85136d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-158951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer